Acadian Asset Management LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.21 - $0.43 $13,428 - $27,496	-63,946 Reduced 26.86%	174,088 $38,000
Q3 2023 Nov 13, 2023	BUY	$0.28 - $0.93 $8,937 - $29,686	31,921 Added 15.49%	238,034 $71,000
Q2 2023 Aug 07, 2023	SELL	$0.55 - $1.26 $41,996 - $96,211	-76,358 Reduced 27.03%	206,113 $145,000
Q1 2023 May 11, 2023	SELL	$0.89 - $2.52 $185,135 - $524,202	-208,017 Reduced 42.41%	282,471 $253,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $500,297 - $3.67 Million	490,488 New	490,488 $578,000

Q3 2021 Nov 12, 2021	SELL	$6.68 - $9.1 $89,144 - $121,439	-13,345 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$7.82 - $9.23 $104,357 - $123,174	13,345 New	13,345 $114,000
Q1 2020 May 11, 2020	SELL	$4.91 - $14.7 $14,229 - $42,600	-2,898 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$9.77 - $15.66 $28,313 - $45,382	2,898 New	2,898 $43,000
Q3 2019 Nov 07, 2019	SELL	$9.59 - $12.0 $111,263 - $139,224	-11,602 Closed	0 $0
Q2 2019 Aug 08, 2019	SELL	$9.54 - $14.96 $40,411 - $63,370	-4,236 Reduced 26.75%	11,602 $123,000
Q1 2019 May 09, 2019	SELL	$10.31 - $14.38 $379,449 - $529,241	-36,804 Reduced 69.91%	15,838 $221,000
Q4 2018 Feb 07, 2019	SELL	$8.63 - $12.4 $300,194 - $431,334	-34,785 Reduced 39.79%	52,642 $535,000
Q3 2018 Oct 30, 2018	BUY	$9.6 - $12.9 $299,145 - $401,976	31,161 Added 55.38%	87,427 $1.05 Million
Q2 2018 Jul 24, 2018	BUY	$8.3 - $16.8 $294,799 - $596,702	35,518 Added 171.19%	56,266 $687,000
Q1 2018 Apr 12, 2018	BUY	$8.1 - $16.0 $168,058 - $331,968	20,748 New	20,748 $204,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.